CI
NVO

Corient IA’s Novo Nordisk NVO Stock Holding History

Corient IA’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.9K Sell
1,750
-2,880
-62% -$124K 0.08% 230
2026
Q1 		$170K Hold
4,630
– – 0.16% 225
2025
Q4 		$236K Sell
4,630
-2,370
-34% -$121K 0.22% 181
2025
Q3 		$388K Sell
7,000
-1,400
-17% -$81.9K 0.29% 134
2025
Q2 		$580K Hold
8,400
– – 0.34% 94
2025
Q1 		$583K Buy
+8,400
New +$694K 0.41% 78

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Corient IA's NVO Position: Q2 2026 in Review

Corient IA reduced its Novo Nordisk (NVO) stake by 62% in Q2 2026, selling an estimated $124K and leaving 1,750 shares worth $83.9K. The position accounts for 0.08% of the portfolio, ranked #230.

Corient IA first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $583K in Q1 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Corient IA held 1,750 shares of Novo Nordisk worth $83.9K as of Q2 2026.
  • Corient IA sold 2,880 Novo Nordisk shares in Q2 2026, an estimated $124K.
  • Novo Nordisk made up 0.08% of Corient IA's portfolio in Q2 2026, its #230 holding.
  • Corient IA first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
  • Corient IA's Novo Nordisk position peaked at $583K in Q1 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.